MiRNA-130a promotes inflammation to accelerate atherosclerosis via the regulation of proliferator-activated receptor γ (PPARγ) expression.

Publisher: KARE publishing Country of Publication: Turkey NLM ID: 101652981 Publication Model: Print Cited Medium: Internet ISSN: 2149-2271 (Electronic) Linking ISSN: 21492263 NLM ISO Abbreviation: Anatol J Cardiol Subsets: MEDLINE

Publication: 2023- : İstanbul, Turkey : KARE publishing
Original Publication: İstanbul, Turkey : Aves, [2015]-

Atherosclerosis*/genetics ; MicroRNAs*/genetics; PPAR gamma/*genetics; Animals ; Human Umbilical Vein Endothelial Cells ; Humans ; Inflammation ; Mice ; Peroxisome Proliferator-Activated Receptors

Objective: In this study, we aimed to evaluate the possible function of miR-130a in atherosclerosis (AS), protection against AS, and its molecular biological mechanism.
Methods: Apoe-/- mice were fed a high-fat diet as the AS mice model. Human umbilical vein endothelial cells (HUVECs) were used as in vitro model. Serum samples or cells were used to measure the expression of inflammation. Serum samples or cells were used to determine MiRNA expression profiles using the edgeR tool from Bioconductor. Western Blot analysis was used to assess protein expressions of proliferator-activated receptor γ (PPARγ) and nuclear factor (NF)-κB.
Results: MiRNA-130a expression was up-regulated in atherosclerotic mice. In addition, over-expression of miRNA-130a promoted inflammation factors [tumor necrosis factor (TNF)-α and interleukin (IL)-1β, IL-6, and IL-8] in the in vitro model of AS. However, down-regulation of miRNA-130a reduced inflammation (suppressed TNF-α, IL-1β, IL-6 and IL-8) in the in vitro model. Furthermore, over-expression of miRNA-130a could also suppress the protein expression of PPARγ and induce NF-κB protein expression in the in vitro model. However, suppression of miRNA-130a induced the protein expression of PPARγ and suppressed NF-κB protein expression in the in vitro model of AS. Activation of PPARγ reduced the pro-inflammatory effects of miRNA-130a on the AS-induced in vitro model.
Conclusion: These results strongly support that miRNA-130a suppression can protect against atherosclerosis through inhibiting inflammation by regulating the PPARγ/ NF-κB expression.

Climacteric. 2016 Aug;19(4):357-63. (PMID: 27138353)
Diabetes Care. 2016 Jan;39(1):139-48. (PMID: 26628419)
Am J Transl Res. 2016 Jun 15;8(6):2650-8. (PMID: 27398148)
Front Physiol. 2018 May 29;9:590. (PMID: 29896109)
Respir Res. 2012 Dec 02;13:110. (PMID: 23199346)
J Neuroimmunol. 2021 Feb 15;351:577458. (PMID: 33360969)
Cell Physiol Biochem. 2017;42(2):808-823. (PMID: 28628920)
J Cardiovasc Transl Res. 2013 Dec;6(6):924-30. (PMID: 23812745)
Dis Model Mech. 2018 Oct 8;11(10):. (PMID: 30305306)
Cell Death Differ. 2017 Dec;24(12):2089-2100. (PMID: 28800130)
Adv Exp Med Biol. 2015;887:53-77. (PMID: 26662986)
PPAR Res. 2012;2012:318613. (PMID: 23251142)
Oncol Rep. 2015 Dec;34(6):3088-96. (PMID: 26398698)
Medicine (Baltimore). 2018 Mar;97(13):e9832. (PMID: 29595698)
Am J Med Sci. 2018 Feb;355(2):140-148. (PMID: 29406041)
Int J Mol Sci. 2017 Mar 16;18(3):. (PMID: 28300760)
J Cardiovasc Pharmacol. 2014 Nov;64(5):407-11. (PMID: 24979391)
Sci Rep. 2016 May 27;6:26745. (PMID: 27228955)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Biochem Biophys Res Commun. 2016 Apr 8;472(3):451-8. (PMID: 26898796)
Mol Med Rep. 2015 Apr;11(4):2921-6. (PMID: 25504154)
Adv Exp Med Biol. 2015;887:79-100. (PMID: 26662987)
In Vivo. 2018 May-Jun;32(3):561-565. (PMID: 29695561)
Int J Clin Exp Pathol. 2015 Mar 01;8(3):2555-64. (PMID: 26045761)
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1738-1747. (PMID: 29954752)

0 (MicroRNAs)
0 (PPAR gamma)
0 (Peroxisome Proliferator-Activated Receptors)
0 (Pparg protein, mouse)

Date Created: 20210909 Date Completed: 20211015 Latest Revision: 20220531

20221213

PMC8443196

10.5152/AnatolJCardiol.2021.56721

34498594